Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 6/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177211 | 0.84 | DRD1 (0.43) | CTSLCTSKRXRANR4A2CTSA | |
| SCHEMBL15380733 | 0.84 | MAPK1 (0.37) | CTSLCTSKMAPK1DHODHBAZ2B | |
| SCHEMBL66551 | 0.76 | PSEN1 (0.36) | CTSKMAPK1RXRACTSAROCK2 | |
| SCHEMBL2216638 | 0.72 | HPGDS (0.49) | WNT3A | |
| SCHEMBL1749307 | 0.70 | MEN1 (0.42) | WNT3ABAZ2B | |
| SCHEMBL28440723 | 0.70 | HSD17B1 (0.63) | — | |
| SCHEMBL2216636 | 0.70 | BRD4 (0.40) | BAZ2B | |
| SCHEMBL1346048 | 0.70 | KDM1A (0.56) | MAPK1GSK3BROCK2 | |
| SCHEMBL186787 | 0.70 | HPGDS (0.43) | — | |
| SCHEMBL30382878 | 0.69 | LDHA (0.52) | BAZ2BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383652-B2 | Biaromatic compounds that modulate PPAR-receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | CTSL 4135/4885CTSK 2184/4885MAPK1 2644/4885 |
| US-20090012129-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS | PPARG, PPARD, PPARA | CTSL 4175/4885CTSK 2854/4885MAPK1 2286/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | CTSL 4178/4885CTSK 2066/4885MAPK1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.